Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | MC3R | P41968 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 9/20 | 0.37 |
| ▸ | AKT1 | P31749 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CHUK | O15111 | 2/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | NNMT | P40261 | 3/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31132417 | 1.00 | SIRT3 (0.42) | SIRT3TDP1SYKTSHRADORA3 | |
| SCHEMBL2575802 | 0.80 | HCAR2 (0.44) | TDP1TSHRKDM4EALDH1A1MAPT | |
| SCHEMBL3663171 | 0.78 | SIRT3 (0.42) | SIRT3TDP1SYKTSHRADORA3 | |
| SCHEMBL24166309 | 0.77 | SIRT3 (0.50) | SIRT3TDP1SYKTSHRADORA3 | |
| Ethane SCHEMBL27643616 | 0.77 | HCAR2 (0.41) | TDP1TSHRKDM4EALDH1A1MAPT | |
| SCHEMBL6856427 | 0.77 | SIRT3 (0.41) | SIRT3TDP1SYKTSHRADORA3 | |
| SCHEMBL1465185 | 0.74 | KDM4E (0.43) | TSHRKDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL15544783 | 0.74 | PARP1 (0.41) | SIRT3TDP1SYKRPS6KB1AKT1 | |
| SCHEMBL18400870 | 0.74 | HSP90AA1 (0.40) | SIRT3TDP1SYKRPS6KB1AKT1 | |
| SCHEMBL15758132 | 0.74 | RPS6KB1 (0.41) | SIRT3TDP1RPS6KB1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116635370-A | Process for preparing N- (bis (4-methoxyphenyl) methyl) -6-oxo-2- (pyridazin-3-yl) -1, 6-dihydropyrimidine-5-carboxamide | 英特维特国际股份有限公司 | 2023-08-22 | — | — | CN | disclosed |
| EP-2473486-B2 | PYRIMIDINES AS HEPCIDINE ANTAGONISTS | VIFOR INT AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| US-10975062-B2 | 4-aminoquinazolinyl compounds as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV | 2021-04-13 | — | — | US | disclosed |
| US-10807969-B2 | Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-20 | — | — | US | disclosed |
| EP-3461820-B1 | METHOD FOR OBTAINING CRYSTALS OF MEGLUMINE SALT OF 1-(5,6-DICHLORO-1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLE-4-CARBOXYLIC ACID | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-29 | — | — | EP | disclosed |
| US-20200095234-A1 | 4-AMINOQUINAZOLINYL COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-26 | — | — | US | disclosed |
| US-20190152955-A1 | MEGLUMINE SALT FORMULATIONS OF 1-(5,6-DICHLORO-1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLE-4-CARBOXYLIC ACID | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-23 | — | — | US | disclosed |
| EP-3461820-A1 | METHOD FOR OBTAINING CRYSTALS OF MEGLUMINE SALT OF 1-(5,6-DICHLORO-1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLE-4-CARBOXYLIC ACID | Janssen Pharmaceutica NV (BE) | 2019-04-03 | — | — | EP | disclosed |
| US-10246442-B2 | 4-Aminoquinazolin compounds as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2019-04-02 | — | — | US | disclosed |
| EP-2758059-B1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME (US) | 2018-10-24 | — | — | EP | disclosed |
| US-20100279974-A1 | Nucleosides With Non-Natural Bases as Anti-Viral Agents | IDENIX PHARMACEUTICALS, INC. | 2010-11-04 | — | — | US | disclosed |
| US-20100279974-A1 | Nucleosides With Non-Natural Bases as Anti-Viral Agents | IDENIX PHARMACEUTICALS, INC. | 2010-11-04 | — | — | US | disclosed |
| WO-2010093727-A1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-19 | — | — | WO | disclosed |
| US-20100204226-A1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-12 | — | — | US | disclosed |
| WO-2009117269-A1 | SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES | MERCK & CO., INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| EP-1898934-A1 | NUCLEOSIDES WITH NON-NATURAL BASES AS ANTI-VIRAL AGENTS | Idenix (Cayman) Limited (KY) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007144686-A1 | NUCLEOSIDES WITH NON-NATURAL BASES AS ANTI-VIRAL AGENTS | IDENIX (CAYMAN) LIMITED (US) | 2007-12-21 | — | — | WO | disclosed |
| US-6114527-A | Process for preparing substituted pyrimidine derivatives | LONZA AG (CH) | 2000-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204226-A1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, EGLN3, EGLN2 | SIRT3 599/4885TDP1 964/4885SYK 3958/4885 |
| US-10975062-B2 | 4-aminoquinazolinyl compounds as prolyl hydroxylase inhibitors | P4HA1, EGLN3, EGLN2 | SIRT3 1745/4885TDP1 642/4885SYK 3116/4885 |
| US-20200095234-A1 | 4-AMINOQUINAZOLINYL COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, EGLN3, EGLN2 | SIRT3 1745/4885TDP1 642/4885SYK 3116/4885 |
| US-20190152955-A1 | MEGLUMINE SALT FORMULATIONS OF 1-(5,6-DICHLORO-1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLE-4-CARBOXYLIC ACID | PAH, P4HA1, SLC16A1 | SIRT3 485/4885TDP1 679/4885SYK 4736/4885 |
| US-10807969-B2 | Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid | PAH, P4HA1, SLC16A1 | SIRT3 485/4885TDP1 679/4885SYK 4736/4885 |
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | HIF1AN, EGLN2, EGLN3 | SIRT3 1023/4885TDP1 3683/4885SYK 3213/4885 |
| US-20100279974-A1 | Nucleosides With Non-Natural Bases as Anti-Viral Agents | PNP, NSUN2, NME2 | SIRT3 1236/4885TDP1 792/4885SYK 4132/4885 |
| US-10246442-B2 | 4-Aminoquinazolin compounds as prolyl hydroxylase inhibitors | P4HA1, EGLN3, EGLN2 | SIRT3 1890/4885TDP1 522/4885SYK 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.